Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Saved in:
| Title: | Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). |
|---|---|
| Authors: | Rapoport, Bernardo1 brapoport@rosebankoncology.co.za, Chua, Daniel2, Poma, Allen3, Arora, Sujata3, Wang, Yan3, Fein, Luis4, Fein, Luis Enrique5 (AUTHOR) |
| Source: | Supportive Care in Cancer. Nov2015, Vol. 23 Issue 11, p3281-3288. 8p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09414355 |
|---|---|
| DOI: | 10.1007/s00520-015-2738-1 |
